Therapeutic Lipidology

ISBN-13: 9781588295514 / Angielski / Twarda / 2007 / 489 str.

Michael H. Davidson; Kevin C. Maki; Peter Toth

Opis

This book is an up-to-date and comprehensive reference on lipidology. It will serve as a stimulus to the reader to continue to learn about the ever changing and fascinating field of therapeutic lipidology. It will also empower readers to improve and extend the lives of the patients they so conscientiously serve.

Recenzje

From the reviews:

"This text focuses on the science of lipidology and the management of lipid disorders. Therapeutic Lipidology is intended for practicing clinicians who manage patients with dyslipidemias. ... The book is well written ... and geared toward advanced-level practitioners. ... Overall, the material is very up-to-date and timely. ... This is an excellent text for clinicians desiring a current reference on lipid metabolism and the pathophysiology of lipid disorders. ... Academic medical centers should also consider purchase of this text for this same reason." (James J Nawarskas, The Annals of Pharmacotherapy, Vol. 42, September, 2008)

Spis treści

Therapeutic Lipidology Table of Contents Chapter 1 Lipoprotein Metabolism and Vascular Biology Brian G. Choi, M.D., M.B.A. Juan J. Badimon, Ph.D. Pedro R. Moreno, M.D. Valentin Fuster, M.D., Ph.D. Lipoprotein Classification Apolipoprotein Classification Lipid Metabolism HDL Metabolism Lipoprotein Metabolism Regulation Lipids in Vascular Biology and Atherothrombosis Chapter 2 Genetic Disorders of Lipoprotein Metabolism Marina Cuchel, M.D., Ph.D. Atif Qasim, M.D. Daniel J. Rader, M.D. Lipid Disorders Involving Elevated Triglycerides Inherited Syndromes of Elevated LDL-Cholesterol Inherited Syndromes of Low LDL-Cholesterol Inherited Syndromes of Low HDL-C Inherited Syndromes of Elevated HDL-C Levels Chapter 3 International Guidelines for Dyslipidemia Management Cathleen E. Maki, R.N., M.S.N., N.P. The Canadian Guidelines The European Guidelines Joint British Societies Guidelines Chapter 4 Pathophysiology and Management of Dyslipidemias Associated with Obesity, Type 2 Diabetes and Other Insulin Resistant States Kevin C. Maki, Ph.D. Obesity and Type 2 Diabetes Mellitus Cardiometabolic Risk Syndrome Lipid Abnormalities Associated with Insulin Resistance Functions of Insulin Excessive Production of Very-low Density Lipoproteins (VLDL): The Primary Lipid Abnormality in the Insulin Resistant State Reasons for Elevated Free Fatty Acid Levels in Insulin Resistant States Formation of Small, Dense LDL Particles Mechanisms Linking Insulin Resistance to Low HDL Cholesterol Activities of Lipoprotein and Hepatic Lipases and Their Relationships to Atherogenic Dyslipidemia Lifestyle Management for Atherogenic Dyslipidemia Drug Therapies for Atherogenic Dyslipidemia Intensification of Efforts to Lower LDL-C as a Means of Achieving the Non-HDL-C Goal Targeting Triglyceride-rich Lipoprotein Reduction as a Means of AchievingNon-HDL-C Goal Management of Diabetic Dyslipidemia Chapter 5 C-Reactive Protein and Other Inflammatory Markers in Cardiovascular Disease Natalie Khuseyinova, M.D. Wolfgang Koenig, M.D., Ph.D. C-reactive Protein Cytokines Markers of Hemostasis, that are also Acute Phase Reactants Plasminogen Activator Inhibitor-1 D-Dimer Von Willebrand Factor White Blood Cell Count Lipid-related Biomarkers Oxidised (Ox) LDL Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Adiponectin Chapter 6 Dietary Prescriptions to Control Dyslipidemias and Coronary Disease Risk Margo A. Denke, M.D. A Diet-Enthusiast's Summary of The Evolving Role of Diet Pre-Statin Cholesterol Lowering (1960-1987) Early Statin Years: LDL Lowering (1987-1994) Landmark Statin Trials, LDL Lowering and Eruption of the Metabolic Syndrome (1994-2004) Lipid Therapy Beyond LDL and CHD Prevention Dietary Therapies Beyond Lipids 2004-present Chapter 7 Pharmacological Therapy for Cardiovascular Disease: Current and Emerging Therapies Michael H. Davidson, M.D., F.A.C.C., F.A.C.P. Statins Ezetimibe Bile Acid Sequestrants Niacin Fibrates Omega-3 Fatty Acids Chapter 8 Effects of Thiazolidinediones on Serum Lipoproteins Anjli Maroo, M.D., R.V.T. W. H. Wilson Tang, M.D., F.A.C.C. Mechanisms of TZD Actions on Serum Lipoproteins Clinical Evidence of Lipid Lowering Effects of TZDs Meta-Analyses of Pioglitazone and Rosiglitazone Trials Prospective Comparative Clinical Studies Concomitant TZD and Statin Therapy Outcome Studies Future Directions Chapter 9 High-Density Lipoproteins Peter P. Toth, M.D., Ph.D. Antiatherogenic Effects of HDL Epidemiologic Studies Evaluating the Relationship between HDL and Risk for Cardiovascular Disease The Definition and Prevalence of Low HDL Effects of Lifestyle Modification on HDL Pharmacologic Therapy for Low

Blurb

Since the creation of the American Board of Clinical Lipidology, many clinicians have wanted an up-to-date, comprehensive reference on lipidology. Now, for the first time, clinicians can find such a reference in Therapeutic Lipidology. This volume will provide practicing clinicians with a focused and intensive but useable source of information on the identification and management of dyslipidemias. Among the topics discussed in this groundbreaking text are lipoprotein metabolism, pharmacological therapy for cardiovascular disease, thiazolidinediones on serum lipoproteins, hypertriglyceridemia, dyslipidemia and obesity, dyslipidemia in children, and much more.

The pace of scientific and clinical advances in lipidology is astounding. This reference will serve as a lifelong stimulus to the reader to continue to learn about the ever changing and fascinating field of therapeutic lipidology. Comprehensive and cutting-edge, Therapeutic Lipidology will empower readers to improve and extend the lives of the patients they so conscientiously serve.